This retrospective study evaluates the diagnostic performance of pediatric thyroid nodule categorization for predicting malignancy when applying the recommended ultrasound risk stratification criteria. Lim-Dunham JE et al. Pediatr Radiol 2017; 47: 429.–436 doi:10.1007/s00247-017-3780-6

In this large prospective study of postmenopausal women, Luo et al. investigate the association between benign breast disease and subsequent risk of thyroid cancer. Luo J, Hendryx M, Nassir R et al. Cancer Causes Control 2017. doi:10.1007/s10552-017-0918-7

Hahn et al. review  the properties of indolent thyroid cancer as identified by clinical data, sonographic features, histopathology, and molecular markers and discuss the management of indolent thyroid cancer. Hahn LD et al. Cancers Head Neck 2017;2:1. doi:10.1186/s41199-016-0021-x

The chapter describes the various different staging systems that have been developed for thyroid cancer and their respective utility. Wartofsky L. In: Thyroid Cancer . Edited by Wartofsky L & Van Nostrand D. Springer New York, 2016. doi:10.1007/978-1-4939-3314-3_9

This chapter provides a summary of the epidemiology of thyroid cancer and the associations between thyroid cancer incidence and certain risk factors. Figge JJ. In: Thyroid Cancer . Edited by Wartofsky L & Van Nostrand D. Humana Press, 2006. doi:10.1007/978-1-59259-995-0_2

Anaplastic thyroid cancer is an aggressive, relatively chemoresistant subtype of thyroid cancer. As discussed in this chapter, aggressive, multimodality therapy currently provides the best opportunity for clinical response. Liebner DA, Haraldsdottir S, & Shah MH. In: Thyroid Cancer . Edited by Wartofsky L & Van Nostrand D. Springer New York, 2016. doi:10.1007/978-1-4939-3314-3_99

Operative treatment for papillary thyroid cancer (PTC) should be thorough without morbidity and tailored to the specific patient situation. This chapter reviews the approach to surgical therapy of PTC. Doherty GM. In: Thyroid Cancer . Edited by Wartofsky L & Van Nostrand D. Springer New York, 2016. doi:10.1007/978-1-4939-3314-3_31

This chapter discusses the role of magnetic resonance imaging and computerized tomography in the evaluation of patients with thyroid cancer. Jelinek J, Young R, Smith III LO, & Burman KD. In: Thyroid Cancer . Edited by Wartofsky L & Van Nostrand D. Springer New York, 2016. doi:10.1007/978-1-4939-3314-3_45

This review describes the changing incidence of thyroid cancer, emphasizing the implications for patients and highlighting ongoing and potential strategies to combat this growing clinical and public health issue. Nat Rev Endocrinol 2016; 12: 646–653. doi:10.1038/nrendo.2016.110

This retrospective review by Geller et al. found that localized and regional medullary thyroid cancer treatment patterns reflect multidisciplinary management based on disease characteristics. Geller G, Laskin J, Cheung WY & Ho C. Thyroid Res 2017; 10:6. doi:10.1186/s13044-017-0041-6

In this study of patients with papillary thyroid carcinoma, dynamic risk stratification was utilized to identify patients with biochemical incomplete response at risk of structural disease recurrence. Zern NK, Clifton-Bligh R, Gill AJ et al. Ann Surg Oncol 2017; 24: 2611-2616. doi:10.1245/s10434-017-5911-6

In this retrospective analysis, Tonorezos et al. report the outcomes of real-world thyroid cancer screening using a physical exam among survivors of childhood, adolescent, and young adult cancer at the Memorial Sloan Kettering Adult Long-Term Follow-Up clinic. Tonorezos ES et al. J Cancer Surviv 2017; 11: 302–308. doi:10.1007/s11764-016-0588-6

Clerc et al. discuss the role of radioiodine treatment  as an adjuvant post-operative treatment for patients with differentiated thyroid cancer. Clerc J et al. Eur J Nucl Med Mol Imaging 2017; 44: 918–925. doi:10.1007/s00259-017-3654-z

This chapter summarizes the revised 2015 American Thyroid Association medullary thyroid cancer (MTC) guidelines and the somewhat contradictory evidence regarding surgical management strategies for sporadic MTC. Scheri RP, Roman SA, & Sosa JA. In: Medullary Thyroid Cancer . Edited by Wang TS & Evans DB. Springer International Publishing, 2016. doi:10.1007/978-3-319-39412-1_11

Up to 98 % of patients with the hereditary form of medullary thyroid cancer  have an identifiable pathogenic mutation in the RET gene. This  chapter reviews the approaches to genetic evaluation and counseling. Geurts JL. In: Medullary Thyroid Cancer . Edited by Wang TS & Evans DB. Springer International Publishing, 2016. doi:10.1007/978-3-319-39412-1_6

This article reviews the recent advances and treatment standards in radioiodine refractory thyroid cancer. Narayanan S & Colevas AD. Curr Treat Options in Oncol  2016; 17: 30. doi:10.1007/s11864-016-0404-6